Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
41
INFIQ Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
1.36%
Day range:
$0.0001 - $0.0001
52-week range:
$0.0000 - $0.0026
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
1.6K
Avg. volume:
9.1K
1-year change:
--
Market cap:
$100
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Infinity Pharmaceuticals, Inc. has 29999900% upside to fair value with a price target of -- per share.
INFIQ vs. S&P 500
-
Over the past 5 trading days, Infinity Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Infinity Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Infinity Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Infinity Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Infinity Pharmaceuticals, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Infinity Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
30.7M
EV / Invested capital:
--
Price / LTM sales:
0.00x
EV / EBIT:
--
EV / Revenue:
11.96x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $1.9M | $2.2M | $2.6M | $686K | $583K | |
| Gross Profit | $279K | $398K | $592K | $152K | $125K | |
| Operating Income | -$41.9M | -$46.7M | -$42M | -$12M | -$10.1M | |
| EBITDA | -$41.4M | -$46.2M | -$41.6M | -$11.9M | -$10M | |
| Diluted EPS | -$0.60 | -$0.53 | -$0.46 | -$0.13 | -$0.11 | |
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65M | $44.8M | $99.7M | $59.6M | $19.9M | |
| Total Assets | $68.4M | $48.7M | $102.6M | $61.9M | $21.2M | |
| Current Liabilities | $8.2M | $8.9M | $10.6M | $14.3M | $12.1M | |
| Total Liabilities | $38.9M | $60M | $61.1M | $63M | $58.6M | |
| Total Equity | $29.6M | -$11.4M | $41.5M | -$1.1M | -$37.4M | |
| Total Debt | $30.6M | $51.3M | $51.2M | $49.6M | $47.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$39.4M | -$41.7M | -$38.9M | -$10.6M | -$8M | |
| Cash From Investing | $13.7M | -$10.8M | $10.7M | $3.3M | -- | |
| Cash From Financing | $94M | $930K | $61K | $28K | $16K | |
| Free Cash Flow | -$39.4M | -$41.7M | -$38.9M | -$10.6M | -$8M | |
INFIQ
Sector
Market Cap
$100
$27.8M
Price % of 52-Week High
0.04%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.55%
1-Year Price Total Return
--
-17.47%
Beta (5-Year)
6.447
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.0000
200-day SMA
Buy
Level
$0.0000
Bollinger Bands (100)
Sell
Level
0.0001 - 0.0001
Chaikin Money Flow
Sell
Level
-204.8M
20-day SMA
Buy
Level
$0.0000
Relative Strength Index (RSI14)
Buy
Level
50.5514
ADX Line
Buy
Level
58.194
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.0001
MACD (12, 26)
Sell
Level
-0.0001
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
349.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, INFIQ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INFIQ average analyst price target in the past 3 months is --.
-
Where Will Infinity Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Infinity Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Infinity Pharmaceuticals, Inc.?
Analysts are divided on their view about Infinity Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Infinity Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Infinity Pharmaceuticals, Inc.'s Price Target?
The price target for Infinity Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INFIQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Infinity Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of INFIQ?
You can purchase shares of Infinity Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Infinity Pharmaceuticals, Inc. shares.
-
What Is The Infinity Pharmaceuticals, Inc. Share Price Today?
Infinity Pharmaceuticals, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Infinity Pharmaceuticals, Inc.. Yesterday, Infinity Pharmaceuticals, Inc. closed at $0.0000 per share.
-
How To Buy Infinity Pharmaceuticals, Inc. Stock Online?
In order to purchase Infinity Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get INFIQ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INFIQ
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
0.00x
1.60x
Growth Metrics
INFIQ
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
INFIQ
Sector
Profitability FY 2025
--
$3.5M
Return on invested capital
--
-31.77%
Return on assets
--
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
INFIQ
Sector
Total cash
--
$26.3M
Short term investments
--
$25.7M
Total assets
--
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
